Cardiovascular medicine Onglyza

ONGLYZA™ is a treatment for patients with type 2 diabetes that has been

developed by an alliance between AstraZeneca and Bristol-Myers Squibb.

ONGLYZA is one of a class of compounds called DPP-4 inhibitors - known as gliptins - that work by enhancing the action of natural hormones in the body called incretins. Incretins decrease elevated blood sugar levels (glucose) by increasing the body's utilization of sugar, mainly through increasing insulin secretion from the pancreas, and by reducing the liver's production of glucose.